Finance

Lists
FTH:NASDAQ
Faeth Therapeutics, Inc
$39.87
+2.23%
(+0.87) 1D
Sep 4, 2:29:14 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for FTH...
Open
$38.35
High
$41.16
Low
$38.35
Mkt. cap
1.03B
Avg. vol.
296.69K
Volume
171.67K
52-wk high
$41.16
52-wk low
$13.43
EPS
-$141.65
Beta
-0.27
Shares outstanding
25.84M
No. of employees
29
Open
$38.35
High
$41.16
Low
$38.35
Mkt. cap
1.03B
Avg. vol.
296.69K
Volume
171.67K
52-wk high
$41.16
52-wk low
$13.43
EPS
-$141.65
Beta
-0.27
Shares outstanding
25.84M
No. of employees
29
News stories
From web sources and news partners
About Faeth Therapeutics, Inc
CEO-
Employees29
Founded1999
HeadquartersAustin, Texas, United States
SectorBiotechnology
Websitefaeththerapeutics.com
Analyst ratings
Based on 9 analysts giving stock ratings to FTH in the past 3 months
Strong buy
Buy
9
Hold
0
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for FTH in the last 3 months.
Highest
Current $39.87
$60.00 (+50.49%)
Average
$56.11 (+40.73%)
Lowest
$51.00 (+27.92%)
Analyst
Recommendation
Action
Price target
Projected
Date
Gil Blum
Needham
Buy
Initiated
$56.00
+40.5%
08/21/2026
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
$60.00
+50.5%
08/11/2026
Jeet Mukherjee
BTIG
Buy
Maintained
$55.00
+37.9%
08/10/2026
Jay Olson
Oppenheimer
Buy
Maintained
$60.00
+50.5%
08/05/2026
Boris Peaker
JonesTrading
Buy
Initiated
$55.00
+37.9%
08/04/2026
Sean McCutcheon
Raymond James
Buy
Initiated
$56.00
+40.5%
07/31/2026
Silvan Turkcan
Citizens JMP
Buy
Initiated
$51.00
+27.9%
07/20/2026
Geoff Meacham
Citi
Buy
Maintained
$55.00
+37.9%
07/16/2026
Jack Allen
Robert W. Baird
Buy
Initiated
$57.00
+43%
06/26/2026
Li Watsek
Cantor Fitzgerald
Buy
Maintained
-
-
06/03/2026
Christopher Liu
Lucid Capital
Buy
Initiated
$50.00
+25.4%
05/28/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
2.54M
2.17M
150.91M
9.18M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.32M
2.79M
19.71M
9.20M
Operating expense
4.85M
4.96M
170.63M
18.38M
Total operating expenses
4.85M
4.96M
170.63M
18.38M
Operating income
-4.85M
-4.96M
-170.63M
-18.38M
Other non operating income
-
-115.00K
-104.00K
120.00K
EBT including unusual items
-4.57M
-4.72M
-170.24M
-16.01M
EBT excluding unusual items
-4.57M
-4.85M
-170.34M
-16.01M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-4.57M
-4.72M
-170.24M
-16.01M
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
289.00K
223.00K
392.00K
2.26M
Interest expense
-6.00K
-3.00K
-
-
Net interest expenses
283.00K
220.00K
392.00K
2.26M
Depreciation and amortization charges
-
-
-
-
EBITDA
-4.82M
-4.92M
-170.60M
-18.36M
Gain or loss from assets sale
1.00K
-21.00K
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps